Publications by authors named "I Jurisinova"
Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19.
View Article and Find Full Text PDFPurpose: The echocardiography parameters may predict the maintenance of sinus rhythm after cardioversion of a supraventricular arrhythmia (SVA).
Materials And Methods: Patients in septic shock with onset of an SVA, normal to moderately reduced LV systolic function (EF_LV˃̳35%) and on a continuous noradrenaline of <1.0 μg/kg.
Aims: A recently published trial has shown no differences in outcomes between patients with new-onset supraventricular arrhythmia (SVA) in septic shock treated with either propafenone or amiodarone. However, these outcome data have not been evaluated in relation to the presence or absence of a dilated left atrium (LA).
Methods And Results: Patients with SVA and a left ventricular ejection fraction ≥ 35% were randomized to receive intravenous propafenone (70 mg bolus followed by 400-840 mg/24 h) or amiodarone (300 mg bolus followed by 600-1800 mg/24 h).
Article Synopsis
- Acute supraventricular arrhythmias can worsen hemodynamic stability in patients with septic shock, and a study compared the effects of intravenous propafenone and amiodarone on arrhythmias in this population.
- In a trial with 209 patients, those receiving propafenone had a quicker return to sinus rhythm (3.7 hours) compared to those on amiodarone (7.3 hours), although the overall 24-hour sinus rhythm rates were similar.
- Propafenone led to fewer cases of arrhythmia recurrence than amiodarone, especially in patients without a dilated left atrium, indicating it may be a more effective option for short-term management.
Purpose: The aim was to verify the impact of obesity on the long-term outcome of patients with severe SARS-CoV-2 ARDS.
Materials And Methods: The retrospective study included patients admitted to the high-volume ECMO centre between March 2020 and March 2022. The impact of body mass index (BMI), co-morbidities and therapeutic measures on the short and 90-day outcomes was analysed.